Asian Pacific Journal of Cancer Prevention

  • 제15권15호
  • /
  • Pages.6295-6300
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer

  • Tian, Shu-Bo (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College) ;
  • Yu, Jian-Chun (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College) ;
  • Kang, Wei-Ming (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College) ;
  • Ma, Zhi-Qiang (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College) ;
  • Ye, Xin (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College) ;
  • Cao, Zhan-Jiang (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College) ;
  • Yan, Chao (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)
  • 발행 : 2014.08.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Our aim was to investigate the value of combined detection of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA 242 and CA 50 in diagnosis and assessment of prognosis in consecutive gastric cancer patients. Clinical data including preoperative serum CEA, CA 19-9, CA 242, and CA 50 values and information on clinical pathological factors were collected and analyzed retrospectively. Univariate and multivariate survival analyses were used to explore the relationship between tumor markers and survival. Positive rates of tumor markers CEA, CA 19-9, CA 242 and CA 50 in the diagnosis of gastric cancer were 17.7, 17.1, 20.4 and 13.8%, respectively, and the positive rate for all four markers combined was 36.6%. Patients with elevated preoperative serum concentrations of CEA, CA 19-9, CA 242 and CA 50, had late clinical tumor stage and significantly poorer overall survival. Five-year survival rates in patients with elevated CEA, CA 19-9, CA 242 and CA 50 were 28.1, 25.8, 27.0 and 24.1%, respectively, compared with 55.0, 55.4, 56.4 and 54.5% in patients with these markers at normal levels (p<0.01). In multivariate Cox proportional hazards analyses, an elevated CA 242 level was determined to be an independent prognostic marker in gastric cancer patients. Combined detection of four tumor markers increased the positive rate for gastric cancer diagnosis. CA 242 showed higher diagnostic value and CA 50 showed lower diagnostic value. In resectable gastric carcinoma, preoperative CA 242 level was associated with disease stage, and was found to be a significant independent prognostic marker in gastric cancer patients.

키워드

참고문헌

  1. Aizawa M, Gotohda N, Takahashi S, et al (2011). Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wall-penetrating gastric cancer. World J Surg, 35, 2717-22. https://doi.org/10.1007/s00268-011-1269-2
  2. Aloe S, D'Alessandro R, Spila A, et al (2003). Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer. Int J Biol Markers. 18, 21-7.
  3. A.M. Attallah, N.A. Al-Ghawalby, A.A.F. Abdel Aziz, et al (2006). Clinical value of serum CEA, CA 19-9, CA 242 and AFP in diagnosis of gastrointestinal tract cancers. Int J Cancer Res, 2, 50-6. https://doi.org/10.3923/ijcr.2006.50.56
  4. Bagaria B, Sood S, Sharma R, Lalwani S (2013). Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med, 10, 148-57.
  5. Carpelan-Holmstrom M, Haglund C, Lundin J, et al (1996). Preoperative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur J Cancer, 32, 1156-61. https://doi.org/10.1016/0959-8049(96)00030-5
  6. Choi SR, Jang JS, Lee JH, et al (2006). Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci, 51, 2081-6. https://doi.org/10.1007/s10620-006-9166-5
  7. Duraker N, Celik AN (2001). The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol, 76, 266-71. https://doi.org/10.1002/jso.1044
  8. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  9. Gonzalez A, Vizoso F, Allende MT, et al (1996). Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma. Int J Biol Markers, 11, 165-71.
  10. Gwak HK, Lee JH, Park SG (2014). Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer. Asian Pac J Cancer Prev, 15, 4933-8. https://doi.org/10.7314/APJCP.2014.15.12.4933
  11. He CZ, Zhang KH, Li Q, et al (2013). Combined use of AFP, CEA, CA125 and CA 19-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol, 14, 13-87.
  12. Hwang GI, Yoo CH, Sohn BH, et al (2004). Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat, 36, 178-81. https://doi.org/10.4143/crt.2004.36.3.178
  13. Johansson C, Nilsson O, Lindholm L (1991). Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg. Int J Cancer, 48, 757-63. https://doi.org/10.1002/ijc.2910480521
  14. Jung MR, Park YK, Jeong O, et al (2011). Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol, 104, 504-10. https://doi.org/10.1002/jso.21986
  15. Kim DY, Kim HR, Shim JH, et al (2000). Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol, 74, 185-92. https://doi.org/10.1002/1096-9098(200007)74:3<185::AID-JSO4>3.0.CO;2-0
  16. Kodera Y, Yamamura Y, Torii A, et al (1996). The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol, 91, 49-53.
  17. Kuusela P, Haglund C, Roberts PJ, Jalanko H (1987). Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Br J Cancer, 55, 673-76. https://doi.org/10.1038/bjc.1987.137
  18. Li F, Li S, Wei L, et al (2013). The correlation between preoperative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment. Biomarkers, 18, 632-37. https://doi.org/10.3109/1354750X.2013.840800
  19. Marrelli D, Pinto E, De Stefano A, et al (2001). Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg, 181, 16-9. https://doi.org/10.1016/S0002-9610(00)00549-3
  20. Marrelli D, Roviello F, De Stefano A, et al (1999). Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology, 57, 55-62. https://doi.org/10.1159/000012001
  21. Mihmanli M, Dilege E, Demir U, et al (2004). The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology, 51, 1544-7.
  22. Mittal A, Gupta SP, Jha DK, et al (2013). Impact of various tumor markers in prognosis of gastric cancer. A hospital based study from tertiary care hospital of Kathmandu valley. Asian Pac J Cancer Prev, 14, 1965-7. https://doi.org/10.7314/APJCP.2013.14.3.1965
  23. Nilsson O, Johansson C, Glimelius B, et al (1992). Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer, 65, 215-21. https://doi.org/10.1038/bjc.1992.44
  24. Ni XG, Bai XF, Mao YL, et al (2005). The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol, 31, 164-9. https://doi.org/10.1016/j.ejso.2004.09.007
  25. Shimada H, Takiguchi N, Kainuma O, et al (2010). High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer. 13, 170-6. https://doi.org/10.1007/s10120-010-0554-3
  26. Sisik A, Kaya M, Bas G, et al (2013). CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. Asian Pac J Cancer Prev, 14, 4289-94. https://doi.org/10.7314/APJCP.2013.14.7.4289
  27. Tachibana M, Takemoto Y, Nakashima Y, et al (1998). Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer. J Am Coll Surg, 187, 64-8. https://doi.org/10.1016/S1072-7515(98)00133-1
  28. Ucar E, Semerci E, Ustun H, et al (2008). Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther, 25, 1075-84. https://doi.org/10.1007/s12325-008-0100-4
  29. Xiao J, He X, Wang Z, et al (2014). Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer. Tumour Biol, 35, 1331-4. https://doi.org/10.1007/s13277-013-1177-1
  30. Yang XQ, Chen C, Peng CW, et al (2012). Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases. Med Oncol, 29, 1030-6. https://doi.org/10.1007/s12032-011-9967-z
  31. Ychou M, Duffour J, Kramar A, et al (2000). Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers, 16, 105-10. https://doi.org/10.1155/2000/595492
  32. Yu H, Liu X (2013). The diagnostic value of CEA combined with CA199, CA724, CA 242 for gastric cancer. Medical Laboratory Science Clinics, 4, 15-6.
  33. Zhu YB, Ge SH, Zhang LH, et al (2012).Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi, 15, 161-4.

피인용 문헌

  1. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis vol.10, pp.11, 2015, https://doi.org/10.1371/journal.pone.0142080
  2. Tumor Markers for Diagnosis, Monitoring of Recurrence and Prognosis in Patients with Upper Gastrointestinal Tract Cancer vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10267
  3. Preoperative Serum CEA and CA19-9 in Gastric Cancer - a Single Tertiary Hospital Study of 1,075 Cases vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2685
  4. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3867
  5. Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis vol.2015, pp.1875-8630, 2015, https://doi.org/10.1155/2015/549843
  6. Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer vol.4, pp.3, 2016, https://doi.org/10.3892/mco.2015.712
  7. Clinicopathological features and prognosis of gastric cancer in young patients vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2489-5
  8. Using gastric juice lncRNA-ABHD11-AS1 as a novel type of biomarker in the screening of gastric cancer vol.37, pp.1, 2016, https://doi.org/10.1007/s13277-015-3903-3
  9. Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3738-y
  10. Prognostic significance of pretreatment serum carcinoembryonic antigen levels in gastric cancer with pathological lymph node-negative: A large sample single-center retrospective study vol.23, pp.48, 2017, https://doi.org/10.3748/wjg.v23.i48.8562
  11. Use of Tumor Markers in Gastrointestinal Cancers: Surgeon Perceptions and Cost-Benefit Trade-Off Analysis vol.24, pp.5, 2017, https://doi.org/10.1245/s10434-016-5717-y
  12. Early postoperative tumor marker responses provide a robust prognostic indicator for N3 stage gastric cancer vol.96, pp.32, 2017, https://doi.org/10.1097/MD.0000000000007560
  13. Golgi protein 73 and its diagnostic value in liver diseases pp.09607722, 2019, https://doi.org/10.1111/cpr.12538
  14. Combined Detection of CA199, CA242 and CA50 in the Diagnosis for Pancreatic Cancer: A Meta Analysis vol.08, pp.04, 2018, https://doi.org/10.12677/ACM.2018.84073
  15. Genome-wide long non-coding RNAs identified a panel of novel plasma biomarkers for gastric cancer diagnosis pp.1436-3305, 2019, https://doi.org/10.1007/s10120-018-00915-7